KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $201.0 million.

  • Pfizer's Share-based Compensation fell 7128.57% to $201.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 216.52%. This contributed to the annual value of $877.0 million for FY2024, which is 6704.76% up from last year.
  • Per Pfizer's latest filing, its Share-based Compensation stood at $201.0 million for Q3 2025, which was down 7128.57% from $203.0 million recorded in Q2 2025.
  • Pfizer's Share-based Compensation's 5-year high stood at $700.0 million during Q3 2024, with a 5-year trough of $86.0 million in Q2 2022.
  • In the last 5 years, Pfizer's Share-based Compensation had a median value of $202.0 million in 2025 and averaged $261.6 million.
  • As far as peak fluctuations go, Pfizer's Share-based Compensation skyrocketed by 36357.62% in 2024, and later tumbled by 7128.57% in 2025.
  • Pfizer's Share-based Compensation (Quarter) stood at $686.0 million in 2021, then fell by 25.95% to $508.0 million in 2022, then crashed by 76.18% to $121.0 million in 2023, then skyrocketed by 478.51% to $700.0 million in 2024, then plummeted by 71.29% to $201.0 million in 2025.
  • Its Share-based Compensation was $201.0 million in Q3 2025, compared to $203.0 million in Q2 2025 and $170.0 million in Q1 2025.